Design and Development of Nanomaterial-Based Drug Carriers to Overcome the Blood–Brain Barrier by Using Different Transport Mechanisms
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Central nervous system (CNS) diseases are the leading causes of death and disabilities in the world. It is quite challenging to treat CNS diseases efficiently because of the blood–brain barrier (BBB). It is a physical barrier with tight junction proteins and high selectivity to limit the substance transportation between the blood and neural tissues. Thus, it is important to understand BBB transport mechanisms for developing novel drug carriers to overcome the BBB. This paper introduces the structure of the BBB and its physiological transport mechanisms. Meanwhile, different strategies for crossing the BBB by using nanomaterial-based drug carriers are reviewed, including carrier-mediated, adsorptive-mediated, and receptor-mediated transcytosis. Since the viral-induced CNS diseases are associated with BBB breakdown, various neurotropic viruses and their mechanisms on BBB disruption are reviewed and discussed, which are considered as an alternative solution to overcome the BBB. Therefore, most recent studies on virus-mimicking nanocarriers for drug delivery to cross the BBB are also reviewed and discussed. On the other hand, the routes of administration of drug-loaded nanocarriers to the CNS have been reviewed. In sum, this paper reviews and discusses various strategies and routes of nano-formulated drug delivery systems across the BBB to the brain, which will contribute to the advanced diagnosis and treatment of CNS diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Astrocyte-endothelial interactions at the blood-brain barrier
Abbott, N. J., Rönnbäck, L., & Hansson, E. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1824 · Cited by 5,595
Structure and function of the blood–brain barrier
Abbott, N. J., Patabendige, A. A. K., Dolman, D. E. M., Yusof, S. R., & Begley, D. J. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.07.030 · Cited by 5,185
Letko, M., Marzi, A., & Munster, V. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0688-y · Cited by 3,109
Ou, X., Liu, Y., Lei, X., Li, P., Mi, D., Ren, L., Guo, L., Guo, R., Chen, T., Hu, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15562-9 · Cited by 3,097
The blood-brain barrier: Bottleneck in brain drug development
Pardridge, W. M. (2005) · NeuroRX · doi:10.1602/neurorx.2.1.3 · Cited by 2,798
Li, Y., Bai, W., & Hashikawa, T. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25728 · Cited by 2,266 · cited 1×
“2 both have affinity to human angiotensin-converting enzyme 2 (hACE2) [24–26], which is expressed in the lungs, heart, kidneys, intestines and brain cells [47,49], although SARSCoV-2 has around 10–20-fold higher affinity [27] and it shares different binding sites [24,50] on interaction with the ACE2 receptor.”
BackgroundBaig, A. M., Khaleeq, A., Ali, U., & Syeda, H. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00122 · Cited by 2,207 · cited 2×
“SARS-CoV-2 is a SARS-like single-stranded RNA coronavirus with 29,903 bp [47], and has high genetic similarity with SARS-CoV (79.”
BackgroundSaraiva, C., Praça, C., Ferreira, R., Santos, T., Ferreira, L., & Bernardino, L. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.05.044 · Cited by 1,609 · cited 1×
“The BBB is one of the most extensive and exclusive physical barriers that maintain homeostasis within the CNS by protecting it from toxins and metabolic fluctuations [6].”
BackgroundMultiple organ infection and the pathogenesis of SARS
Gu, J., Gong, E., Zhang, B., Zheng, J., Gao, Z., Zhong, Y., Zou, W., Zhan, J., Wang, S., Xie, Z., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050828 · Cited by 1,379
Netland, J., Meyerholz, D. K., Moore, S., Cassell, M., & Perlman, S. (2008) · Journal of Virology · doi:10.1128/jvi.00737-08 · Cited by 1,293
Overcoming the blood–brain tumor barrier for effective glioblastoma treatment
van Tellingen, O., Yetkin-Arik, B., de Gooijer, M. C., Wesseling, P., Wurdinger, T., & de Vries, H. E. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.02.002 · Cited by 1,035
Transport of drugs across the blood–brain barrier by nanoparticles.
Wohlfart, S., Gelperina, S., & Kreuter, J. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.08.017 · Cited by 715
CNS Delivery Via Adsorptive Transcytosis
Hervé, F., Ghinea, N., & Scherrmann, J.-M. (2008) · The AAPS Journal · doi:10.1208/s12248-008-9055-2 · Cited by 676
Nanomaterial-based blood-brain-barrier (BBB) crossing strategies
Xie, J., Shen, Z., Anraku, Y., Kataoka, K., & Chen, X. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119491 · Cited by 604
Ulbrich, K., Hekmatara, T., Herbert, E., & Kreuter, J. (2009) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2008.08.021 · Cited by 591
Blood–Brain Barrier Transport of Therapeutics via Receptor-Mediation
Jones, A. R., & Shusta, E. V. (2007) · Pharmaceutical Research · doi:10.1007/s11095-007-9379-0 · Cited by 549 · cited 2×
“However, the percentage of administered drug reaching the brain via this way is usually below 1–4%, due to the low permeability and the poor BBB selectivity, which means that the remaining 96–99% of the drug is off-target and would be potentially responsible for the systemic side effects, mainly phagocytosed by monocy…”
BackgroundCrossing the Blood–Brain Barrier: Recent Advances in Drug Delivery to the Brain
Patel, M. M., & Patel, B. M. (2017) · CNS Drugs · doi:10.1007/s40263-016-0405-9 · Cited by 430 · cited 1×
“Some cationic molecules, such as cationized albumin [96,103] and wheat germ agglutinin [104], may have a relatively strong binding affinity for anionic sites on the surface of endothelial cells because of the electrostatic interaction.”
BackgroundSurface-Modified Nanocarriers for Nose-To-Brain Delivery: From Bioadhesion to Targeting
Sonvico, F., Clementino, A. R., Buttini, F., Colombo, G., Pescina, S., Stanisçuaski Guterres, S., Raffin Pohlmann, A., & Nicoli, S. (2018) · doi:10.20944/preprints201802.0077.v1 · Cited by 306 · cited 7×
“A small portion of the drug administered into the nasal cavity also enters the general circulation, and then it can reach the brain after crossing the BBB [140,141].”
BackgroundMethodInfluentialDoes SARS‐Cov‐2 invade the brain? Translational lessons from animal models
Natoli, S., Oliveira, V., Calabresi, P., Maia, L. F., & Pisani, A. (2020) · European Journal of Neurology · doi:10.1111/ene.14277 · Cited by 260 · cited 1×
“2 both have affinity to human angiotensin-converting enzyme 2 (hACE2) [24–26], which is expressed in the lungs, heart, kidneys, intestines and brain cells [47,49], although SARSCoV-2 has around 10–20-fold higher affinity [27] and it shares different binding sites [24,50] on interaction with the ACE2 receptor.”
BackgroundCeña, V., & Játiva, P. (2018) · Nanomedicine · doi:10.2217/nnm-2018-0139 · Cited by 232 · cited 1×
“The initial progress of transcytosis is the uptake of NPs by endocytosis [100].”
BackgroundViral disruption of the blood–brain barrier
Spindler, K. R., & Hsu, T.-H. (2012) · Trends in Microbiology · doi:10.1016/j.tim.2012.03.009 · Cited by 219 · cited 6×
“The disruption of the BBB is both a cause and effect of viral-induced CNS diseases [11].”
BackgroundInfluentialNanoparticle transport across the blood brain barrier
Grabrucker, A. M., Ruozi, B., Belletti, D., Pederzoli, F., Forni, F., Vandelli, M. A., & Tosi, G. (2016) · Tissue Barriers · doi:10.1080/21688370.2016.1153568 · Cited by 217 · cited 7×
“Furthermore, the endothelial cells are tightly packed then connected through adherens junctions (AJs) and tight junctions (TJs) (Figure 1B) [5,8,9].”
BackgroundInfluentialClaxton, A., Baker, L. D., Wilkinson, C. W., Trittschuh, E. H., Chapman, D., Watson, G. S., Cholerton, B., Plymate, S. R., Arbuckle, M., & Craft, S. (2013) · Journal of Alzheimer’s Disease · doi:10.3233/jad-122308 · Cited by 215
shRNA and siRNA delivery to the brain
Pardridge, W. M. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.03.008 · Cited by 176 · cited 1×
“Transferrin receptor is a transmembrane glycoprotein, responsible for the iron uptake via endo-and exocytosis of Tf [126].”
BackgroundHSV-1 and Alzheimer’s disease: more than a hypothesis
Piacentini, R., De Chiara, G., Li Puma, D. D., Ripoli, C., Marcocci, M. E., Garaci, E., Palamara, A. T., & Grassi, C. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00097 · Cited by 130 · cited 1×
“O th er vi ru se s HSV Bloodstream and neuronal route [33]; Up-regulate MMP2 and MMP9 and disrupt BBB [34];”
BackgroundCerebrospinal Fluid Biomarkers of Neurovascular Dysfunction in Mild Dementia and Alzheimer'S Disease
Sweeney, M. D., Sagare, A. P., & Zlokovic, B. V. (2015) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2015.76 · Cited by 122
Mouse Adenovirus Type 1-Induced Breakdown of the Blood-Brain Barrier
Gralinski, L. E., Ashley, S. L., Dixon, S. D., & Spindler, K. R. (2009) · Journal of Virology · doi:10.1128/jvi.00954-09 · Cited by 70 · cited 1×
“MAV-1 Stimulate an innate host response to induce BBB disruption [36]; Possible invasion by a Trojan horse mechanism via monocytes [37,38];”
BackgroundHerpes viruses and Alzheimer's disease: new evidence in the debate
Balin, B. J., & Hudson, A. P. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30316-8 · Cited by 38 · cited 1×
“Flaviviruses are major emerging human pathogens, and some of the flaviviruses, such as West Nile virus (WNV), Japanese encephalitis virus (JEV), Dengu virus and Zika virus, are regarded to invade the CNS by various mechanisms [40,41].”
BackgroundZhang, C.-X., Zhao, W.-Y., Liu, L., Ju, R.-J., Mu, L.-M., Zhao, Y., Zeng, F., Xie, H.-J., Yan, Y., & Lu, W.-L. (2015) · Oncotarget · doi:10.18632/oncotarget.5354 · Cited by 38
Cited by
Functionalized Nanomaterials Capable of Crossing the Blood–Brain Barrier
Zha, S., Liu, H., Li, H., Li, H., Wong, K.-L., & All, A. H. (2024) · ACS Nano · doi:10.1021/acsnano.3c10674 · Cited by 378
The barrier and interface mechanisms of the brain barrier, and brain drug delivery
Zhang, S., Gan, L., Cao, F., Wang, H., Gong, P., Ma, C., Ren, L., Lin, Y., & Lin, X. (2022) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2022.09.017 · Cited by 129
Poudel, P., & Park, S. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14040835 · Cited by 124
Ding, L., Kshirsagar, P., Agrawal, P., & Murry, D. J. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17060706 · Cited by 62
Metadata
- Authors
- Song, J., Lu, C., Leszek, J., & Zhang, J.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2021-09-19
- Volume
- 22
- Issue
- 18
- Pages
- 10118
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W3199136853
- Cited by
- 91
- References
- 29
- FWCI
- 3.87
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.